Predicting T Cell-Inflamed Gene Expression Profile in Hepatocellular Carcinoma Based on Dynamic Contrast-Enhanced Ultrasound Radiomics

References

• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu Z, Gao J, et al. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma. Front Immunol. 2022;13:964190.
   PubMed Web of Science ®Google Scholar
• Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–1469.
   PubMed Web of Science ®Google Scholar
• Haber PK, Castet F, Torres-Martin M, et al. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology. 2023;164(1):72–88.e18.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599–1611.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Atri M, Jang H-J, Kim TK, Khalili K. Contrast-enhanced US of the Liver and Kidney: a Problem-solving Modality. Radiology. 2022;303(1):11–25.
   PubMed Web of Science ®Google Scholar
• Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762.
   PubMed Web of Science ®Google Scholar
• Mayerhoefer ME, Materka A, Langs G, et al. Introduction to Radiomics. J Nucl Med. 2020;61(4):488–495.
   PubMed Web of Science ®Google Scholar
• Turco S, Tiyarattanachai T, Ebrahimkheil K, et al. Interpretable Machine Learning for Characterization of Focal Liver Lesions by Contrast-Enhanced Ultrasound. IEEE Trans Ultrason Ferroelectr Freq Control. 2022;69(5):1670–1681.
   PubMed Web of Science ®Google Scholar
• Liu F, Liu D, Wang K, et al. Deep Learning Radiomics Based on Contrast-Enhanced Ultrasound Might Optimize Curative Treatments for Very-Early or Early-Stage Hepatocellular Carcinoma Patients. Liver Cancer. 2020;9(4):397–413.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu F, Xie X, et al. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol. 2020;30(4):2365–2376.
   PubMed Web of Science ®Google Scholar
• Dong Y, Zuo D, Qiu YJ, Cao JY, Wang HZ, Wang WP. Prediction of Histological Grades and Ki-67 Expression of Hepatocellular Carcinoma Based on Sonazoid Contrast Enhanced Ultrasound Radiomics Signatures. Diagnostics. 2022;12(9):2175.
   Web of Science ®Google Scholar
• Bitencourt AGV, Gibbs P, Rossi Saccarelli C, et al. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. EBioMedicine. 2020;61:103042.
   PubMed Web of Science ®Google Scholar
• Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180–1191.
   PubMed Web of Science ®Google Scholar
• Qi Y, Zhao T, Han M. The application of radiomics in predicting gene mutations in cancer. Eur Radiol. 2022;32(6):4014–4024.
   PubMed Web of Science ®Google Scholar
• Feng Z, Li H, Liu Q, et al. CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma. Radiology. 2023;307(1):e221291.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, Phase II clinical trial. J Immunother Cancer. 2022;10(4):e004656.
   PubMedGoogle Scholar
• Chow P, Chen M, Cheng A-L, et al. IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or ablation. Presented at: 2023 AACR Annual Meeting; April 14-19, 2023; Orlando, Florida.
   Google Scholar
• Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506–515.
   PubMed Web of Science ®Google Scholar
• Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): a Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2021;27(4):1003–1011.
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, Phase 2-3 study. Lancet Oncol. 2021;22(7):977–990.
   PubMed Web of Science ®Google Scholar
• Yu SJ. Immunotherapy for hepatocellular carcinoma: recent advances and future targets. Pharmacol Ther. 2023;244:108387.
   PubMed Web of Science ®Google Scholar
• Chen S, Feng S, Wei J, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol. 2019;29(8):4177–4187.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
   PubMed Web of Science ®Google Scholar
• Radiology ACo. CEUS LI-RADS® v2017 CORE. Available from: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUS-LI-RADS-2017-Core.pdf. Accessed August 29, 2023.
   Google Scholar
• Qin X, Hu X, Xiao W, Zhu C, Ma Q, Zhang C. Preoperative Evaluation of Hepatocellular Carcinoma Differentiation Using Contrast-Enhanced Ultrasound-Based Deep-Learning Radiomics Model. J Hepatocell Carcinoma. 2023;10:157–168.
   PubMed Web of Science ®Google Scholar
• Li CQ, Zheng X, Guo HL, et al. Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017. BMC Med Imaging. 2022;22(1):36.
   PubMed Web of Science ®Google Scholar
• Wang W, Wu SS, Zhang JC, et al. Preoperative Pathological Grading of Hepatocellular Carcinoma Using Ultrasomics of Contrast-Enhanced Ultrasound. Acad Radiol. 2021;28(8):1094–1101.
   PubMed Web of Science ®Google Scholar
• Turhon M, Li M, Kang H, et al. Development and validation of a deep learning model for prediction of intracranial aneurysm rupture risk based on multi-omics factor. Eur Radiol. 2023.
   PubMedGoogle Scholar
• Aggen DH. Combining Biomarkers for Immunotherapy. Cancer Discov. 2018;8(12):1500–1501.
   Web of Science ®Google Scholar
• Liang J, Ding T, Guo ZW, et al. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer. 2013;109(4):1031–1039.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu Z, Zhang X, et al. Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers. ESMO Open. 2020;5(6):e000910.
   PubMed Web of Science ®Google Scholar
• Lam LHT, Chu NT, Tran TO, Do DT, Nqk L. A Radiomics-Based Machine Learning Model for Prediction of Tumor Mutational Burden in Lower-Grade Gliomas. Cancers. 2022;14(14):3492.
   PubMed Web of Science ®Google Scholar
• Pei Q, Yi X, Chen C, et al. Pre-treatment CT-based radiomics nomogram for predicting microsatellite instability status in colorectal cancer. Eur Radiol. 2022;32(1):714–724.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Klein C, Caruso S, et al. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol. 2022;77(1):116–127.
   PubMed Web of Science ®Google Scholar
• Gu Y, Huang H, Tong Q, et al. Multi-View Radiomics Feature Fusion Reveals Distinct Immuno-Oncological Characteristics and Clinical Prognoses in Hepatocellular Carcinoma. Cancers. 2023;15(8):2338.
   PubMed Web of Science ®Google Scholar
• Prasanna P, Tiwari P, Madabhushi A. Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe): a new radiomics descriptor. Sci Rep. 2016;6:37241.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhao Y, Lin P, et al. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ. BMC Med Imaging. 2021;21(1):84.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680.
   PubMed Web of Science ®Google Scholar